touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) discusses his recent phase II study exploring the benefits, efficacy and safety of tyrosine kinase inhibitors dasatinib–blinatumomab for the treatment of Ph-positive acute lymphoblastic leukemia in adults.
Questions
- What is the rationale for the use of dasatinib plus glucocorticoids, followed by blinatumomab, rather than chemotherapy, in the treatment of adults with newly diagnosed? Ph+ acute lymphoblastic leukemia? 00:12-02:30
- Could you give us a brief overview of the Phase II study investigating this regimen? 02:30-04:14
- What were the efficacy, safety and tolerability findings of the study? 04:14-07:02
- Which patients are most likely to benefit from this regimen? 07:02-08:39
- What questions remain unanswered and what future studies are planned? 08:39-11:43
- Please summarise the findings from the ancillary studies? 11:43-13:42
- Please discuss the importance of laboratory testing, home treatment and the benefits of this approach during the COVID-19 pandemic 13:42-16:13
Speaker Disclosure: Robin Foà has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
